• Home
  • Search Results

Search Results

Cancer - Multiple Myeloma
44 studies match your search
Open

Phase 2 Relapsed or Refractory Multiple Myeloma Study

Have you been diagnosed with relapsed or refractory multiple myeloma? If so you may be able to take part in a research study looking at the safety and efficacy of giving BMS-986393 to patients with multiple myeloma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Open

Cancer Family History in Black Families

The survey and its findings will help us understand attitudes around cancer family history and genetic testing among Black people. This information will be used to develop an educational curriculum to strive towards health equity for Black people diagnosed with or at higher risk of cancer and get Black people the best cancer care.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 18 more)
  • Healthy Volunteer or General Population
  • Minority Health
Visit Location
100% Remote (online, phone, text)

Daratumumab infusion reaction study for patients with multiple myeloma

The purpose of this research study is to learn more about the risk of severe and fatal infusion-related reactions (IRR) in patients with multiple myeloma who are treated with their first 3 administrations of daratumumab. Examples of severe IRR include lung tightness, low oxygen levels, difficulty breathing, high blood pressure, racing heart, headache, and too much fluid in the lungs. No fatal IRRs have been observed in clinical trials of daratumumab. We are also doing this study to help us to identify potential risk factors for IRR.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Coming Soon

A Phase II Study of CyBorD Plus Daratumumab for Patients with MGRS

The purpose of this study is to find out whether a combination of drugs is a safe treatment for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. The combination of drugs in this study is cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC. In addition, we will find out whether the study drug combination is an effective treatment for these conditions.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
  • Kidneys and Liver
Open

Cancer Research Study for Bertie, Hertford, Robeson & Scotland Co, NC and neighboring counties

We are seeking volunteers for a survey to learn what may encourage and discourage cancer patients to be in cancer research studies. We'd like to hear from you if you are: -18 years+ -Have been diagnosed with cancer or the caregiver of someone diagnosed with cancer. -Spend time in Bertie, Hertford, Robeson or Scotland County, NC or a neighboring county. Participation includes 1 survey (about 10 minutes long) that can be done with your mobile device, computer, or by phone with the researcher. Compensation: 1 in 10 participants will receive a $25 Visa gift card.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 20 more)
Visit Location
100% Remote (online, phone, text)
Not currently enrolling

Financial Assistance Research

We would like to learn about how people who apply for healthcare financial assistance experience the application process, including things that make the application process work well or that were challenging. At this time we are not able to offer interviews to people who applied to UNC or Duke, we are interested in hearing from people who applied to other programs (such as Atrium, Novant, Wake, Vidant, ECU, Cape Fear Health Net, Physicians Reach Out, or Project Access).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Aging
  • Behavior
  • Blood Pressure
  • and 44 more
Visit Location
100% Remote (online, phone, text)

Young Adult Cancer Survivors Healthy Eating and Active Lifestyle Study

We are doing this study to test a behavioral lifestyle program designed specifically for adolescent and young adult cancer survivors. Study participants will use a smartphone app and Fitbit activity tracker to help them develop healthier habits.

Age & Gender
  • 18 years ~ 39 years
  • Male, Female, Gender Inclusive
Study Interest
  • Behavior
  • Eating, Nutrition, and Metabolism
  • Wellness and Lifestyle
  • and 3 more
Visit Location
100% Remote (online, phone, text)
Open

ETERNITY: Biorepository to accelerate advances in Radiation Therapy

Have you been diagnosed with cancer or a benign disease that is being evaluated for cancer for which you may receive treatment? If so, you may be able to take part in a research study that collects biospecimens (e.g. blood, saliva, tissue, etc) and health information to better understand how cancers develop and affect the body,]. If so, you may be able to take part in a research study that aims to identify non-invasive biomarkers for cervical cancer screening and monitoring following treatment of abnormal areas on the cervix caused by HPV.

Age & Gender
  • 0 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 20 more)
  • Child and Teen Health
Open

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Open

Phase 2 study of isatuximab plus lenalidomide and dexamethasone in highly toxicity-vulnerable subjects with newly diagnosed multiple myeloma

Do you have newly-diagnosed multiple myeloma? If so, you may be able to participate in a research study looking at the safety, efficacy, and tolerability of giving isatuximab in combination with lenalidomide and dexamethasone at lower doses.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research